The GLP-1 receptor agonist liraglutide promotes fat breakdown and browning in obese mice through activation of COX-2 signaling, and blocking COX-2 abolishes these metabolic benefits.
COX-2 inhibition abolished liraglutide's fat-burning effectsWhen the COX-2 enzyme was blocked, liraglutide could no longer promote fat breakdown, browning, or adaptive thermogenesis — revealing COX-2 as an essential mediator of GLP-1 metabolic benefits.
What the researchers found
Liraglutide (1 mg/kg/day) improved insulin resistance and reduced body weight and fat mass in high-fat diet-induced obese mice. At the cellular level, liraglutide suppressed adipocyte hypertrophy (fat cell enlargement) and upregulated browning markers PGC1α, UCP1, and ATGL in both obese adipose tissues and cultured 3T3-L1 adipocytes.
Metabolomics analysis revealed that liraglutide elevated COX-2 signaling and prostaglandin levels in subcutaneous fat. Critically, COX-2 inhibition completely abolished liraglutide's effects on adipogenesis and lipolysis, and impaired adaptive thermogenesis during cold exposure. This demonstrates that COX-2 activation is required for liraglutide's fat-burning effects.
Why it matters
Understanding how GLP-1 drugs burn fat is crucial for optimizing their use and predicting drug interactions. The finding that COX-2 is essential for liraglutide's fat-metabolizing effects has immediate clinical implications: millions of patients take COX-2 inhibitors (like celecoxib) or NSAIDs (like ibuprofen) alongside GLP-1 agonists. If these anti-inflammatory drugs blunt the fat-burning benefits of GLP-1 therapies, it could affect treatment outcomes for obese patients.
How the study worked
In vivo: High-fat diet-induced obese mice received liraglutide (1 mg/kg/day) and were assessed for metabolic parameters, body weight, fat mass, and adipose tissue histology. In vitro: Differentiated 3T3-L1 adipocytes were treated with liraglutide with and without COX-2 inhibition. Non-targeted metabolomics was performed on subcutaneous adipose tissue. Cold exposure experiments tested the role of COX-2 in adaptive thermogenesis.
What this study cannot tell us
This is a mouse study using a single dose of liraglutide, and results may not directly translate to humans. The specific COX-2 inhibitor used and its dosing were not detailed in the abstract. Whether this mechanism applies equally to other GLP-1 receptor agonists (semaglutide, tirzepatide) was not tested. The clinical significance of COX-2 involvement in human patients taking GLP-1 drugs remains to be established.
How to read the evidence
This is a preclinical study combining in vivo mouse experiments with in vitro cell culture and metabolomics analysis. The multi-modal approach provides strong mechanistic evidence, but translation to human clinical relevance requires further study.
When this study was published
Published in 2025, this is a very recent study that addresses a timely mechanistic question about GLP-1 receptor agonists during a period of explosive growth in their clinical use worldwide.
The bigger picture
This study adds a new piece to the puzzle of how GLP-1 receptor agonists exert their wide-ranging metabolic benefits. The COX-2 connection is particularly significant because it bridges peptide hormone signaling with inflammatory pathways in fat tissue — two systems not previously linked in this way. It also raises practical questions about drug-drug interactions that affect the millions of patients co-prescribed GLP-1 agonists and anti-inflammatory medications.
Questions still open
- Do common NSAIDs and COX-2 inhibitors reduce the weight loss effectiveness of GLP-1 receptor agonists in human patients?
- Is the COX-2 mechanism specific to liraglutide, or does it apply to other GLP-1 receptor agonists like semaglutide?
- Could targeting COX-2 activation specifically in adipose tissue enhance the fat-burning benefits of GLP-1 therapy?
Common questions
Could taking ibuprofen reduce the weight loss effects of GLP-1 drugs?
What is fat 'browning' and how does liraglutide promote it?
Read the original research
Activation of cyclooxygenase-2 signaling mediates liraglutide-induced adipose lipolytic activity.
European journal of pharmacology, 1006, 178133
Citation
Li, Jingyi; Wu, Hailian; Ma, Wenhui; Yuan, Tao; Chen, Xiaopan; Pan, Yong. (2025). Activation of cyclooxygenase-2 signaling mediates liraglutide-induced adipose lipolytic activity.. European journal of pharmacology, 1006, 178133. https://doi.org/10.1016/j.ejphar.2025.178133